[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100105037":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":26,"centralContacts":11,"locations":30,"responsibleParty":48,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Bayer","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL",null,[13],"Drug: BAY86-4891 (Estradiol \u002F Drospirenone)",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm 2",[13],[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","BAY86-4891 (Estradiol \u002F Drospirenone)","Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles",[9],{"type":19,"name":20,"description":24,"armGroupLabels":25,"otherNames":11},"Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles",[15],[27],{"name":28,"affiliation":5,"role":29},"Bayer Study Director","STUDY_DIRECTOR",[31,43],{"facility":11,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":11},"Berlin","State of Berlin","10115","Germany","DE",{"type":38,"coordinates":39},"Point",[40,41],13.41053,52.52437,{"lat":41,"lon":40},{"facility":11,"status":11,"city":32,"state":33,"zip":44,"country":35,"countryCode":36,"cosmosGeoPoint":45,"geoPoint":47,"contacts":11},"13353",{"type":38,"coordinates":46},[40,41],{"lat":41,"lon":40},{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100105037","phase-2-a-study-to-evaluate-inhibition-of-ovulation-of-two-oral-estrogenprogestogen-regimens-in-healthy-young-females-over-a-period-of-3-treatment-cycles-100105037",false,"NCT00631124","A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen\u002FProgestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles","A Double-blind, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Oral Estradiol \u002F Drospirenone Regimens in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles","Inclusion Criteria:\n\n* Healthy female volunteers,\n* Age 18 - 35 years\n\nExclusion Criteria:\n\n* Contraindications for use of a combined (estrogen\u002Fprogestogen) contraceptive (e.g. history of venous\u002Farterial thromboembolic disease)\n* Regular intake of medication\n* Clinically relevant findings (ECG, blood pressure, physical, gynecological examination, laboratory examination)\n* Anovulatory pre-treatment cycle",true,"FEMALE","18 Years","35 Years",{"count":62,"type":63},103,"ACTUAL","INTERVENTIONAL",[66],"PHASE2","Investigation of a new pill containing an estrogen and a progestin in order to monitor the inhibition of the ovulation in young healthy females over 3 treatment cycles",[69],"Contraception",[69],"COMPLETED","2014-11-28",{"date":74,"type":75},"2014-12-02","ESTIMATED",{"date":77,"type":11},"2008-02",{"date":79,"type":63},"2008-12",{"name":5,"class":6},2]